ATRA Atara Biotherapeutics Inc: Multiplikator Forward P/S

Atara Biotherapeutics (ATRA) strives for global leadership in immunopharmacy through the development of its T-cell platform. On GURU.Markets, the projected price-to-sales ratio demonstrates market expectations, where 20.30 serves as the current parameter value. The uniqueness of the donor method provides the issuer with significant pricing power, while a focus on retaining leading scientists and regulatory experts ensures the stability of the R&D core.

This ratio compares the current market value of Atara Biotherapeutics (ATRA) with expected annual revenues, measuring the premium investors are willing to pay per unit of future revenue. By analyzing the forward P/S valuation, the market assesses the growth potential of the company, whose R&D expenses and cash flow have been stabilized through strategic alliances with European pharmaceutical corporations and royalties.